Page last updated: 2024-09-03

gefitinib and Chordoma

gefitinib has been researched along with Chordoma in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Asquith, CRM; Drewry, DH; East, MP; Havener, TM; Johnson, GL; Laitinen, T; Morris, DC; Naegeli, KM; Wells, CI; Zuercher, WJ1
Adkins, J; Byron, S; Cuyugan, L; Dardis, C; Enriquez, D; Helland, A; Liang, WS; Little, AS; Sekar, S1
Amary, F; Barnard, M; Brüderlein, S; Cottone, L; Drewry, DH; Flanagan, AM; Guppy, N; Jorgensen, M; Leite, AP; Leithner, A; Möller, P; Pillay, N; Scheipl, S; Smith, JA; Strauss, SJ; Tirabosco, R; Turlais, F; Ye, H; Zuercher, WJ1
Kjellén, E; Lindén, O; Stenberg, L1
Debus, J; Hof, H; Welzel, T1

Other Studies

5 other study(ies) available for gefitinib and Chordoma

ArticleYear
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
    Journal of medicinal chemistry, 2019, 05-09, Volume: 62, Issue:9

    Topics: Aminoquinolines; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chordoma; Drug Design; ErbB Receptors; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines

2019
Identification of therapeutic targets in chordoma through comprehensive genomic and transcriptomic analyses.
    Cold Spring Harbor molecular case studies, 2018, Volume: 4, Issue:6

    Topics: Adult; Aged; Ataxia Telangiectasia Mutated Proteins; Checkpoint Kinase 2; Chordoma; Cyclin-Dependent Kinase 4; DNA-Binding Proteins; Female; Gefitinib; Gene Expression Profiling; Genomics; Humans; Male; Middle Aged; Mutation; Nuclear Proteins; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-3; Receptor, Fibroblast Growth Factor, Type 1; Skull Base Neoplasms; Transcription Factors; Transcriptome

2018
EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
    The Journal of pathology, 2016, Volume: 239, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chordoma; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mice; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays

2016
Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib.
    Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cervical Vertebrae; Cetuximab; Chordoma; Female; Gefitinib; Humans; Middle Aged; Quinazolines; Spinal Cord Compression

2009
Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma.
    Onkologie, 2006, Volume: 29, Issue:12

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chordoma; Gefitinib; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Sacrum; Spinal Neoplasms; Treatment Outcome

2006